ABSTRACT
BACKGROUND: Stereo-electroencephalography (SEEG) is a well-known invasive diagnostic method for drug-resistant epilepsy (DRE). Its rate of complications is relatively low, being the intracranial hemorrhage (ICH) the most relevant. Most centers perform immediate imaging studies after SEEG to rule out complications. However, delayed intracranial hemorrhages (DIH) can occur despite normal imaging studies in the immediate postoperative period. METHODS: We performed a retrospective review of DRE pediatric patients operated on SEEG between April 2016 and December 2020 in our institution. After implantation, an immediate postoperative CT was performed to check electrode placement and rule out acute complications. An additional MRI was performed 24 h after surgery. We collected all postoperative hemorrhages and considered them as major or minor according to Wellmer´s classification. RESULTS: Overall, 25 DRE patients were operated on SEEG with 316 electrodes implanted. Three ICHs were diagnosed on postoperative imaging. Two of them were asymptomatic requiring no treatment, while the other needed surgical evacuation after clinical worsening. The total risk of hemorrhage per procedure was 12%, but just one third of them were clinically relevant. Two hemorrhages were not visible on immediate postoperative CT, being incidentally diagnosed in the 24 h MRI. We recorded them as DIH and are reported in detail. CONCLUSION: Few reports of DIH after SEEG exist in the literature. It remains unclear whether these cases are late occurring hemorrhages or immediate postoperative hemorrhages undiagnosed on initial imaging. According to our findings, we recommend to perform additional late postoperative imaging to diagnose these cases and manage them accurately.
Subject(s)
Delayed Diagnosis , Drug Resistant Epilepsy , Child , Drug Resistant Epilepsy/surgery , Electrodes, Implanted , Electroencephalography , Humans , Intracranial Hemorrhages/diagnostic imaging , Intracranial Hemorrhages/etiology , Retrospective Studies , Stereotaxic TechniquesABSTRACT
El acetato de eslicarbazepina (ESL) es un fármaco antiepiléptico (FAE) de tercera generación de la familia de las carboxamidas y estructuralmente relacionado con la carbamazepina y la oxcarbazepina, aunque presenta diferencias farmacológicas que pueden tener implicaciones de utilidad clínica relevantes. Desde 2009, en Europa, el ESL está indicado para su utilización en adultos como terapia adyuvante en pacientes con crisis de inicio parcial (actualmente denominada de inicio focal), con o sin generalización secundaria (con o sin evolución a tonicoclónica bilateral, en terminología actual). En 2017, la indicación como tratamiento adyuvante de los pacientes con crisis de inicio parcial con o sin generalización secundaria se amplió a su utilización en monoterapia en adultos y en combinación en adolescentes y niños mayores de 6 años. Un grupo de expertos realizó esta revisión orientada a la práctica clínica del uso de ESL en población pediátrica, incluyendo aquellos puntos diferenciales respecto a otros FAE. Se han incluido aspectos como la eficacia, dosificación, respuesta clínica en función de la edad, tolerabilidad y su manejo, perfil neurocognitivo y conductual, necesidad de control de algún parámetro analítico, papel de la monitorización de los niveles plasmáticos, posible valor añadido de la administración única, situaciones clínicas en las que sería recomendable la adición de ESL, utilización con otros bloqueantes de los canales del sodio, realización del cambio desde carbamazepina/oxcarbazepina, potenciales interacciones con otros FAE, potenciales interacciones con otros fármacos distintos de los FAE, y algunas consideraciones prácticas que requieren una investigación adicional
Eslicarbazepine acetate (ESL) is a third-generation antiepileptic drug (AED) of the carboxamide family and structurally related to carbamazepine and oxcarbazepine, although it has pharmacological differences that may have relevant implications of clinical utility. Since 2009 in Europe, ESL has been indicated for use in adults as adjuvant therapy in patients with partial-onset seizures (currently called focal-onset), with or without secondary generalization (with or without evolution to bilateral tonic-clonic, in current terminology). In 2017, the indication for adjunctive therapy of patients with partial-onset seizures with or without secondary generalization was extended to its use as monotherapy in adults and as adjuvant therapy in adolescents and children older than 6 years. A group of experts carried out this review aimed at the aspects of most interest in the clinical practice of the use of ESL in the pediatric population, including differential aspects from other AEDs. Aspects such as efficacy, dosage, clinical response depending on age, tolerability and its management, neurocognitive and behavioral profile, need for monitoring of any analytical parameter, role of plasma level monitoring, possible added value of the once-daily administration, clinical situations in which the addition of ESL would be recommended, use with other sodium channel blockers, how to switch from carbamazepine/oxcarbazepine, potential interactions with other AEDs, potential interactions with drugs other than AEDs, and some practical issues that require additional research
Subject(s)
Humans , Child , Adolescent , Dibenzazepines/therapeutic use , Anticonvulsants/therapeutic use , Epilepsies, Partial/drug therapy , Age Factors , Treatment OutcomeABSTRACT
Multinodular and vacuolating neuronal tumor (MVNT) is a rare newly identified benign lesion, firstly included in the World Health Organization classification of tumors of the central nervous system in 2016, whose neoplastic or dysplastic nature remains unclear but with a distinctive cytoarchitectural pattern and radiological features. It is usually discovered as late-onset refractory epilepsy, headache related, or an incidental lesion of adulthood. As it is typically a stable disease, many opt for follow-up, as long as it keeps remaining asymptomatic, leaving surgery for refractory epilepsy, neurological deficits, or intracranial hypertension symptoms. A subtotal or complete resection seems to control seizures and neurological manifestations. We herein present the case of a child with refractory epilepsy related to MVNT and focal cortical dysplasia, a dual pathology case in a less frequent age group and without the typical radiological imaging. We report its radiologic features, histologic description, and management, and we present a brief literature review on MVNT focusing on the pediatric cases reported. MVNT should now be another probable low-grade epilepsy-associated lesion (LEAT) in patients of all ages, with a benign and stable course as it constitutes a curable cause of focal epilepsy. As all the refractory cases, surgery should be indicated after a comprehensive evaluation of a multidisciplinary epilepsy surgery team.
